丙型肝炎抗病毒治疗：口服药物改变了什么?

doi:10.3969/j.issn.1672-5069.2016.04.001

摘要/Abstract

Key words: Hepatitis C, Direct-acting antiviral agents, Progress

罗碧芬, 魏来. 丙型肝炎抗病毒治疗：口服药物改变了什么?[J]. 实用肝脏病杂志, 2016, 19(4): 385-389.

Luo Bifen, Wei Lai. Is hepatitis C eradicated possible[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 385-389.

[1] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南（2015更新版）. 中华肝脏病杂志,2015,23（12）:906-923.
[2] Kowdley KV,Gordon SC,Reddy KR,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med,2014,370（20）:1879-1888.
[3] Afdhal N,Zeuzem S,Kwo P,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med,2014,370（20）:1889-1898.
[4] Feld JJ,Kowdley KV,Coakley E,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med,2014,370（17）:1594-1603.
[5] Zeuzem S,Jacobson IM,Baykal T,et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med,2014,370（17）:1604-1614.
[6] Afdhal N,Reddy KR,Nelson DR,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med,2014,370（16）:1483-1493.
[7] Poordad F,Hezode C,Trinh R,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med, 2014,370（21）:1973-1982.
[8] Brown RS Jr, O'Leary JG, Reddy KR, et al. Hepatitis C therapeutic registry research network study group. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl, 2016,22（1）:24-33.
[9] Pillai AA,Wedd J,Norvell JP,et al. Simeprevir and sofosbuvir （SMV-SOF） for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: A real world （Transplant） hepatology practice experience. Am J Gastroenterol,2016,111（2）:250-260.
[10] Younossi ZM,Bacon BR,Dieterich DT,et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat,2016,23（6）:447-454.
[11] Sulkowski MS,Vargas HE,Di Bisceglie AM,et al. HCV-TARGET Study Group.Effectiveness of simeprevir plus sofosbuvir,with or without ribavirin,in real-world patients with HCV genotype 1 infection. Gastroenterology,2016,150（2）:419-429.
[12] Backus LI,Belperio PS,Shahoumian TA,et al. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology,2016 Apr 26. doi:10.1002/hep.28625[ahead of print].
[13] Zuckerman E,Ashkenasi E,Kovalev Y,et al. Te real-world Israeli experience of treating chronic hepatitis C,genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombita
svir,dasabuvir with or without ribavirin:a large multi-center cohort. J Hepatol,2016,64（supplement 2）:s137.
[14] Cheung MCM,Foster GR,Irving WL,et al. Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/daclatasvir with or without ribavirin 6 and 12 month outcomes compared to untreated patients. J Hepatol,2016,64（supplement 2）:s185.
[15] http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-20
16/en/16]European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol, 2015,63（1）:199-236.
[17] AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing,managing,and treating adults infected with hepatitis C virus. Hepatology, 2015,62（3）:932-954.
[18] Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens. J Hepatol, 2016 Apr 13. pii: S0168-8278（16）30108-8. doi:10.1016/j.jhep.2016.04.006.
[19] Colombo M,Aghemo A,Liu L,et al. Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection. J Hepatol, 2016,64（supplement 2）:s183.
[20] Wang C,Ji D,Chen J,et al. Hepatitis B reactivation in CHC Chinese treated with pan-oral DAAs-a prospective study. Hepatol Int,2016,10 （Suppl 1）:S51.
[21] Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 2016 Apr 11. pii: S0016-5085（16） 30055-5. doi:10.1053/j.gastro.2016.04.003.
[22] Susser S,Dietz J,Vermehren J,et al. European RAVs database: frequency and characteristics of RAVs in treatment naive and DAA-experienced patients. J Hepatol,2016,64（supplement 2）:s139.
[23] Gane EJ,Shiffman ML,Etzkorn K,et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens:results of the GS-US-342-1553 study. J Hepatol,2016,64（supplement 2）:s147.
[24] Poordad F,Gordon SC,Asatryan A,et al. High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the magellan-I study. J Hepatol,2016,64（supplement 2）:s160.
[25] Shiratori Y,Imazeki F,Moriyama M,et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med,2000,132（7）:517-524.
[26] Yoshida H,Arakawa Y,Sata M,et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology,2002,123（2）:483-491.
[27] Shiratori Y,Shiina S,Teratani T,et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med, 2003,138（4）:299-306.

丙型肝炎抗病毒治疗：口服药物改变了什么?

Is hepatitis C eradicated possible

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[4]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[5]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[6]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[7]	张婷婷（综述）, 王煊（审校）. 肝硬化患者口服葡萄糖耐量试验临床意义及研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 449-452.
[8]	孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159.
[9]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[10]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[11]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[12]	杨珍杰,李洪涛,王剑,李霞,陈媛. 聚乙二醇化干扰素α-2a联合利巴韦林治疗代偿期丙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 232-235.
[13]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[14]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[15]	嵇小琴综述, 龚健审校. 老年CHC临床特点及抗病毒治疗策略研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 995-998.